The type 2 diabetes therapy market will steadily expand over the 2019-2029 study period, fueled by increasing prevalence and high unmet need for drugs that can effectively control the disease in the long term. A rich pipeline of novel agents is expected to launch, promoting sustained market growth. However, these novel therapies predominantly represent later-to-market entrants from existing drug classes or novel combination therapies of existing compounds. Among the drug classes expected to undergo the fastest growth are the sodium/glucose cotransporter 2 (SGLT 2) inhibitors—due to the cardiovascular (CV) benefit demonstrated by Jardiance—and the glucagon-like peptide 1 (GLP 1) receptor agonists—due to their efficacy, potential for weight loss, and the CV benefit associated with Victoza and Ozempic. However, these therapies will face major challenges in uptake, including reimbursement hurdles and an increasingly stringent regulatory environment.